These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2897304)

  • 1. Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs.
    McDevitt DG
    Eur Heart J; 1987 Dec; 8 Suppl M():9-14. PubMed ID: 2897304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance.
    Borchard U
    Clin Physiol Biochem; 1990; 8 Suppl 2():28-34. PubMed ID: 1982759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents.
    Meier J
    Am Heart J; 1982 Aug; 104(2 Pt 2):364-73. PubMed ID: 6125095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)].
    Lemmer B
    Herz; 1982 Jun; 7(3):168-78. PubMed ID: 6124492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.
    Nattel S; Gagne G; Pineau M
    Clin Pharmacokinet; 1987 Nov; 13(5):293-316. PubMed ID: 2891461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of metabolic drug interactions involving beta-adrenoceptor blocking drugs.
    Park BK
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):3S-10S. PubMed ID: 6146338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronopharmacokinetics of beta-receptor blocking drugs of different lipophilicity (propranolol, metoprolol, sotalol, atenolol) in plasma and tissues after single and multiple dosing in the rat.
    Lemmer B; Winkler H; Ohm T; Fink M
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Jul; 330(1):42-9. PubMed ID: 2864639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade.
    McDevitt DG; Brown HC; Carruthers SG; Shanks RG
    Clin Pharmacol Ther; 1977 May; 21(5):556-66. PubMed ID: 15753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology.
    Ågesen FN; Weeke PE; Tfelt-Hansen P; Tfelt-Hansen J;
    Pharmacol Res Perspect; 2019 Aug; 7(4):e00496. PubMed ID: 31338197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.
    Riddell JG; Harron DW; Shanks RG
    Clin Pharmacokinet; 1987 May; 12(5):305-20. PubMed ID: 2886244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Beta blockers in migraine prophylaxis].
    Shimizu T
    Brain Nerve; 2009 Oct; 61(10):1125-30. PubMed ID: 19882938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characteristics of beta blockers and their role in clinical practice.
    McDevitt DG
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S5-11. PubMed ID: 2439820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
    Johnsson G; Regàrdh CG
    Clin Pharmacokinet; 1976; 1(4):233-63. PubMed ID: 13958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the stereoisomers of beta-adrenoceptor antagonists in conscious A-V blocked dogs.
    Boucher M; Duchêne-Marullaz P; Moundanga JL
    Br J Pharmacol; 1986 Sep; 89(1):119-27. PubMed ID: 2879587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subsidiary class III effects of beta blockers? A comparison of atenolol, metoprolol, nadolol, oxprenolol and sotalol.
    Manley BS; Alexopoulos D; Robinson GJ; Cobbe SM
    Cardiovasc Res; 1986 Oct; 20(10):705-9. PubMed ID: 2878723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.
    Bouchard J; Shepherd G; Hoffman RS; Gosselin S; Roberts DM; Li Y; Nolin TD; Lavergne V; Ghannoum M;
    Crit Care; 2021 Jun; 25(1):201. PubMed ID: 34112223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enantioselective bioanalysis of beta-blocking agents: focus on atenolol, betaxolol, carvedilol, metoprolol, pindolol, propranolol and sotalol.
    Egginger G; Lindner W; Vandenbosch C; Massart DL
    Biomed Chromatogr; 1993; 7(6):277-95. PubMed ID: 7905307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of beta-adrenoceptor blocking drugs in hyperthyroidism.
    Feely J; Peden N
    Drugs; 1984 May; 27(5):425-46. PubMed ID: 6144501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal delivery of beta-blockers.
    Aqil M; Sultana Y; Ali A
    Expert Opin Drug Deliv; 2006 May; 3(3):405-18. PubMed ID: 16640500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-adrenoceptor blockers and the blood-brian barrier.
    Neil-Dwyer G; Bartlett J; McAinsh J; Cruickshank JM
    Br J Clin Pharmacol; 1981 Jun; 11(6):549-53. PubMed ID: 6115665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.